Pan-Flt3 Inhibitor for the Treatment of Acute Myeloid Leukemia (Aml)

Technology #ua14-071

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Neil Shah
Associate Professor, Medicine
Brendan Frett
Postdoctoral Research Associate I, Pharmacology and Toxicology
Hong Yu Li
Associate Professor, Pharmacology and Toxicology
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Background:  Acute myeloid leukemia (AML) is an aggressive blood cancer and the standard treatment for AML is a chemotherapy regimen developed in the 1970s. Currently, treatment options for AML are limited and represent a major unmet therapeutic need. FLT3 is an enzyme that is found to be mutated in thirty five percent of the people with AML, thus FLT3 inhibitor would represents a significant improvement in treating patients with AML. 


Invention:  UAFLT-2 and UAFLT-3 are most potent FLT3 inhibitors developed to date. The inhibitors are not only selective for the WT FLT3 but also selective for FLT3 mutants. The unprecedented activity and selectivity of UAFLT-2 and UAFLT-3 will likely lead to substantial clinical success in both relapsed and new cases of AML


Applications:  Small Molecule Drug


Advantages:  UAFLT-2 and UAFLT-3 have significant drug properties (extremely small and potent)


Lead Inventors:  Hong-Yu Li, Brendan Frett


Status:  Provisional Patent Application; seeking commercial partner to license


UA ID:  UA14-071